Trial Profile
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUPER
- Sponsors AstraZeneca
- 13 Jun 2017 Primary endpoint of change in glycosylated hemoglobin A1c (HbA1c) from baseline to Week 24 has been met, according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 13 Jun 2017 Results (n=462) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 15 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.